Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
BACKGROUND
There is no curative treatment for Alzheimer's disease (AD). Ginseng is widely used in the treatment of AD in Asian countries.


OBJECTIVE
To evaluate the effectiveness and safety of ginseng for AD.


METHODS
We searched seven main databases for randomized clinical trials (RCTs) on ginseng for AD from their inception to December 2014. The Cochrane risk of bias tool was used to assess the methodological quality. We used RevMan 5.2 to synthesize the results.


RESULTS
Four RCTs involving 259 participants were identified for this systematic review. The methodological quality of included studies was not promising. All comparisons were made between combined treatment (ginseng plus conventional treatment) versus conventional treatment. The results of meta-analyses and several individual studies showed that the effectiveness of combined treatment was inconsistent as measured by MMSE, ADAS-cog, ADAS-noncog, and CDR. No studies reported the outcomes of quality of life (QoL). The current data did not report serious adverse events.


CONCLUSIONS
This review showed that the effects of ginseng on AD were still inconclusive. The main limitations of the available studies were small sample sizes, poor methodological qualities and no placebo controls. Larger, well-designed studies are needed to test the effect of ginseng on AD in the future.
Yuyi
Y
Wang
Guoyan
G
Yang
Juan
J
Gong
Fang
F
Lu
Qingchun
Q
Diao
Jin
J
Sun
Kang
K
Zhang
Jinzhou
J
Tian
Center for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China. Liujp@bucm.edu.cn.
Jianping
J
Liu
D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D006801:Humans; D005894:Panax / Q000737:chemistry*; D010936:Plant Extracts / Q000737:chemistry / Q000302:isolation & purification / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D010936:Plant Extracts